COVID-19 antiviral Articles
-
Using AI to Fight a Pandemic: Insilico Medicine Announces Novel Preclinical Candidate for COVID-19 Treatment
Insilico Medicine announced the nomination of a novel preclinical therapeutic candidate for treating COVID-19, designed using the generative chemistry AI platform Chemistry42. The new drug candidate is a 3CL protease inhibitor unique from existing drugs in its class because it can be rapidly produced. While this nomination is a potentially important development for the ongoing COVID-19 pandemic ...
-
Paxlovid: Spring of Caronic Anhydrides
On February 16, 2022, the data on Paxlovid previously published by Pfizer and submitted to the FDA were published in the New England Journal of Medicine (NEJM). This NEJM article published viral load data that Paxlovid reduced viral load by 0.868 log10 compared to controls for 5 days of treatment, which equates to a remarkable 7.38-fold reduction in viral load. This pivotal study (NCT04960202) ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you